AgroAmerica Supports Higher Education to Help Reduce Migration in Latin America
24.3.2021 14:00:00 EET | Business Wire | Press release
The Agribusiness food company, AgroAmerica, is sponsoring the 100K Innovation Fund grant competition for higher education projects aimed at universities in The United States, Central America and the Dominican Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005218/en/
The 100,000 Strong in the Americas Innovation Fund Grant Competition for higher education, promoted by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala, and the NGO Partners of the Americas, aims to impulse education initiatives through innovative models of academic training and student exchange programs between the United States and Central America & Dominican Republic, beginning in January 2022. Institutions of higher education in the United States and Guatemala, El Salvador, Honduras, Costa Rica, Panama, Belize, Nicaragua, and the Dominican Republic are invited to submit their 100K grant proposals to Partners of the Americas at 100kstrongamericas.org/grants before August 2, 2021. (Photo: Business Wire)
The 100K Innovation Fund New Grant Competition is sponsored by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala and the NGO Partners of the Americas. The 100K Fund will be awarded in 12 grants of $25,000 this year to support new higher education projects.
AgroAmerica is the second multinational company in Guatemala to join this public-private initiative. The company's CEO, Fernando Bolaños Valle, said that "it is with great enthusiasm that AgroAmerica joins the State Department as a strategic partner in this regional initiative, in an organic way, because of our shared values; building, through educational programs, a more prosperous future full of hope for our countries… we are convinced that the future of our continent depends on strategic investments like these, which will multiply prosperity for the United States, Guatemala and the region."
Javier Aguirre, corporate director of AgroAmerica, explained that the company donated funds to strengthen local capacities in the areas of climate change, human rights, natural resource management, sustainable agriculture, conservation and reforestation, environmental protection and sustainable businesses.
"The new 100K Strong Americas Innovation Fund partnerships, supported by AgroAmerica and the Department of State, will grow the number of students in the United States, Central America and the Dominican Republic, so working together, they will acquire valuable new skills and knowledge and grow our economies," said Julie Chung, acting assistant secretary of the Bureau of Western Hemisphere Affairs at the U.S. Department of State.
About the 100K Innovation Fund
The 100,000 Strong in the Americas Innovation Fund is the public-private sector collaboration between the Department of State, U.S. embassies and Partners of the Americas to promote a positive agenda for the region by harnessing the power of education.
About AgroAmerica
AgroAmerica is an agribusiness company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. It operates in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. The Company's Corporate Sustainability Strategy aims to generate value and balance between economic growth, natural resource conservation, and the wellbeing of customers, employees, and stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005218/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom